Active Biotech regains rights of laquinimod from Teva
Teva finally dumps laquinimod, ending failure-riddled saga | Fierce Biotech
Teva, Active Biotech Present Positive Findings for RRMS Experimental Therapy Laquinimod
Placebo-Controlled Trial of Oral Laquinimod for Multiple Sclerosis | NEJM
Heart Incidents End Parts of Two Studies by Teva, Active Biotech - WSJ
After Multiple Failures, Teva Returns Laquinimod Rights to Active Biotech | BioSpace
Teva and Active Signs Agreement to Study Laquinimod as Treatment for Neurological Disease
Letter to investigators involved in the Arpeggio study of Laquinimod …
Laquinimod prevents cuprizone-induced demyelination independent of Toll-like receptor signaling
Laquinimod senkt Schubrate und Progressionsrisiko - 06 - 2012 - Heftarchiv - AMT
laquinimod
CONCERTO: A randomized, placebo-controlled trial of oral laquinimod in relapsing-remitting multiple sclerosis - Giancarlo Comi, Yuval Dadon, Nissim Sasson, Joshua R Steinerman, Volker Knappertz, Timothy L Vollmer, Alexey Boyko, Patrick Vermersch, Tjalf
Swedish Biotech Faces Another Phase III Flop in Multiple Sclerosis
Teva backs laquinimod for MS despite CHMP rejection - PMLiVE
Laquinimod Therapy in Multiple Sclerosis: A Comprehensive Review | SpringerLink
Laquinimod arrests experimental autoimmune encephalomyelitis by activating the aryl hydrocarbon receptor | PNAS
Laquinimod arrests experimental autoimmune encephalomyelitis by activating the aryl hydrocarbon receptor | PNAS
Laquinimod arrests experimental autoimmune encephalomyelitis by activating the aryl hydrocarbon receptor | PNAS
Linomide - Wikipedia
Dark horse laquinimod reveals potential as MS pill | Evaluate
Laquinimod, a Quinoline-3-Carboxamide, Induces Type II Myeloid Cells That Modulate Central Nervous System Autoimmunity | PLOS ONE
